Tomohiro Fujiwara1,2, Yusuke Tsuda3, Jonathan Stevenson3, Michael Parry3, Lee Jeys3. 1. Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK. tomomedvn@gmail.com. 2. Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. tomomedvn@gmail.com. 3. Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK.
Abstract
PURPOSE: Chordoma is a rare but highly aggressive primary bone sarcoma that arises commonly from the sacrum. While en bloc resection has been the mainstay of the treatment, the role of resection margin in millimetres with/without adjuvant radiotherapy (RT) has been unknown. We investigated the prognostic impact of surgical margin width, adjuvant RT, and their combined factor for sacral chordoma. METHODS: Forty-eight patients who underwent surgical treatment between 1996 and 2016 were studied. Of these, 11 patients (23%) received adjuvant RT; photon RT in 7 (15%) and proton RT in 4 (8%). Margins were microscopically measured in millimetres from the resection surface to the closest tumour on histologic slides. RESULTS: The five year and ten year disease-specific survival was 88% and 58%, respectively, and the local recurrence (LR) rate was 48%. The LR rate with 0-mm, < 1.5-mm, and ≥ 1.5-mm margin was 50% (group 1), 50% (group 2: RT-, 61%; group 3: RT+, 14%), and 0% (group 4), respectively. We observed a significantly lower LR rate in patients with adjuvant photon/proton RT (18%) than without it (57%; p = 0.026), and no LR was observed after post-operative proton RT. The combined factor of margin with RT clearly stratified the LR risk: patients of group 1 (positive margin) and 2 (< 1.5-mm margin, RT-) had approximately 7.5× LR risk (p = 0.049) compared with those of group 3 (< 1.5-mm margin, RT+) and 4 (≥ 1.5-mm margin). CONCLUSION: This study identified the lowest risk of local failure in tumour resection with ≥ 1.5-mm margin or negative but < 1.5-mm margin with the use of adjuvant photon/proton radiotherapy for sacral chordoma. Early results of adjuvant proton RT demonstrated excellent local control.
PURPOSE:Chordoma is a rare but highly aggressive primary bone sarcoma that arises commonly from the sacrum. While en bloc resection has been the mainstay of the treatment, the role of resection margin in millimetres with/without adjuvant radiotherapy (RT) has been unknown. We investigated the prognostic impact of surgical margin width, adjuvant RT, and their combined factor for sacral chordoma. METHODS: Forty-eight patients who underwent surgical treatment between 1996 and 2016 were studied. Of these, 11 patients (23%) received adjuvant RT; photon RT in 7 (15%) and proton RT in 4 (8%). Margins were microscopically measured in millimetres from the resection surface to the closest tumour on histologic slides. RESULTS: The five year and ten year disease-specific survival was 88% and 58%, respectively, and the local recurrence (LR) rate was 48%. The LR rate with 0-mm, < 1.5-mm, and ≥ 1.5-mm margin was 50% (group 1), 50% (group 2: RT-, 61%; group 3: RT+, 14%), and 0% (group 4), respectively. We observed a significantly lower LR rate in patients with adjuvant photon/proton RT (18%) than without it (57%; p = 0.026), and no LR was observed after post-operative proton RT. The combined factor of margin with RT clearly stratified the LR risk: patients of group 1 (positive margin) and 2 (< 1.5-mm margin, RT-) had approximately 7.5× LR risk (p = 0.049) compared with those of group 3 (< 1.5-mm margin, RT+) and 4 (≥ 1.5-mm margin). CONCLUSION: This study identified the lowest risk of local failure in tumour resection with ≥ 1.5-mm margin or negative but < 1.5-mm margin with the use of adjuvant photon/proton radiotherapy for sacral chordoma. Early results of adjuvant proton RT demonstrated excellent local control.
Entities:
Keywords:
Chordoma; Margin width; Radiotherapy; Sacrum; Surgery
Authors: Matthew T Houdek; Peter S Rose; Mario Hevesi; Joseph H Schwab; Anthony M Griffin; John H Healey; Ivy A Petersen; Thomas F DeLaney; Peter W Chung; Michael J Yaszemski; Jay S Wunder; Francis J Hornicek; Patrick J Boland; Franklin H Sim; Peter C Ferguson Journal: J Surg Oncol Date: 2019-02-07 Impact factor: 3.454
Authors: Péter Pál Varga; Zsolt Szövérfi; Charles G Fisher; Stefano Boriani; Ziya L Gokaslan; Mark B Dekutoski; Dean Chou; Nasir A Quraishi; Jeremy J Reynolds; Alessandro Luzzati; Richard Williams; Michael G Fehlings; Niccole M Germscheid; Aron Lazary; Laurence D Rhines Journal: Eur Spine J Date: 2014-12-23 Impact factor: 3.134
Authors: M Mima; Y Demizu; D Jin; N Hashimoto; M Takagi; K Terashima; O Fujii; Y Niwa; T Akagi; T Daimon; Y Hishikawa; M Abe; M Murakami; R Sasaki; N Fuwa Journal: Br J Radiol Date: 2013-11-28 Impact factor: 3.039